아시아인 및 라틴계 인구의 폐암 검진을 위한 EGFR ctDNA 정량적 평가 (EQUAL)
동일: 아시아인 및 라틴계 인구의 폐암 검진을 위한 EGFR ctDNA 정량적 평가
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.
The name of the test used in this research study is:
-Circulating free DNA (cfDNA) Assay
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The goal of this research study is to evaluate the feasibility of a novel EGFR blood plasma ctDNA screening test among East Asian and Latinx participants at risk for lung cancer and ineligible for regular lung cancer screening. The test looks for a gene change called Epidermal Growth Factor Receptor (EGFR), specifically EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. This study seeks to determine if it is possible to use the blood test to detect this type of lung cancer that might not yet show symptoms.
The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group.
It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Fernando Pacheco
- 전화번호: 857-215-2794
- 이메일: fernando_pacheco@dfci.harvard.edu
연구 연락처 백업
- 이름: Kylee Coonradt
- 전화번호: 617-582-8846
- 이메일: kylee_coonradt@dfci.harvard.edu
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute
-
연락하다:
- Narjust Florez, MD
- 전화번호: 617-582-7335
- 이메일: narjust_florez@dfci.harvard.edu
-
수석 연구원:
- Narjust Florez, MD
-
Boston, Massachusetts, 미국, 02215
- 아직 모집하지 않음
- Beth Israel Deaconess Medical Center
-
연락하다:
- Daniel Costa, MD, PhD
- 전화번호: 617-667-7000
- 이메일: dbcosta@bidmc.harvard.edu
-
수석 연구원:
- Daniel Costa, MD, PhD
-
Boston, Massachusetts, 미국, 02215
- 아직 모집하지 않음
- Massachusetts General Hospital
-
연락하다:
- Lecia Sequist, MD, MPH
- 전화번호: 617-726-5130
- 이메일: lvsequist@mgb.org
-
수석 연구원:
- Lecia Sequist, MD, MPH
-
Brighton, Massachusetts, 미국, 02135
- 아직 모집하지 않음
- Dana-Farber Cancer Institute at Steward St. Elizabeth's
-
연락하다:
- Alys Malcolm, MD
- 전화번호: 617-632-4595
- 이메일: alys_malcolm@dfci.harvard.edu
-
수석 연구원:
- Alys Malcolm, MD
-
Methuen, Massachusetts, 미국, 01844
- 아직 모집하지 않음
- Dana-Farber Cancer Instiute Merrimack Valley
-
수석 연구원:
- Pedro Sanz-Altamira, MD
-
연락하다:
- Pedro Sanz-Altamira, MD
- 전화번호: 978-620-2020
- 이메일: pedro_sanz-altamira@dfci.harvard.edu
-
South Weymouth, Massachusetts, 미국, 02190
- 아직 모집하지 않음
- Dana-Farber Cancer Institute South Shore
-
연락하다:
- Shail Maingi, MD
- 전화번호: 781-624-5000
- 이메일: shail_maingi@dfci.harvard.edu
-
수석 연구원:
- Shail Maingi, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria (Aims 1, 2, and 3)
Group 1 - Healthy Individuals (50-80 years of age):
Non-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.
Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.
Latinx/Hispanic includes those who self-identify as a person of Central or South American or Caribbean culture or origin.
Countries of origin include:
East Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.
Southeast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.
Latinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
Group 2 - At-Risk Individuals (40-80 years of age):
Non-tobacco using (currently).
Individuals of any race or ethnicity who meet at least one of the following criteria:
Family history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled corticosteroids, or chronic bronchitis.
Symptoms of lung cancer for the past month, including unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.
Excluding individuals who concurrently present with a viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.
Additional Inclusion Criteria for Groups 1 and 2:
Aims 1 and 2: Able to complete and understand the study's informed consent in their preferred language.
Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:
Having had a chest CT scan in the last 12 months or having an anticipated chest CT scan during the enrollment period.
Having a current cancer or history of cancer within the last 3 years, excluding localized skin cancer, breast ductal carcinoma in situ, and localized prostate cancer.
Hemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.
Not able to comply with study requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 상영
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ctDNA Assay
All participants will be asked to provide blood samples and are administered a baseline questionnaire. The blood sample will be tested using the investigational ctDNA assay. If the investigational test is positive, these participants will be followed up by CLIA verification of results. A positive CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. Participants will be notified of results. Additionally, participants may participant in optional studies: 1) One-time survey regarding perception of lung cancer screening and ctDNA testing, 2) Virtual focus group, 3) Blood banking study |
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Detection Rate of Non-Small Cell Lung Cancer
기간: 2 years
|
The proportion of participants with a positive assay result who are subsequently diagnosed with lung cancer through clinical pathology, among all participants tested with the assay. |
2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Testing Turnaround Time
기간: Up to 2 years
|
The duration from the time of blood draw to the release of the ctDNA testing results to the study team. |
Up to 2 years
|
|
Recruitment Acceptability
기간: Up to 2 years
|
Determining proportion of screened patients who are eligible and who consent to the trial at each collaboration site |
Up to 2 years
|
|
Barriers to Sample Acquisition
기간: Up to 2 years
|
Examining barriers impeding scale-up of sample collection, handling, and delivery |
Up to 2 years
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Narjust Florez, MD, Dana-Farber Cancer Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 24-415
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 공유 기간
Data can be shared no earlier than 1 year following the date of publication
IPD 공유 액세스 기준
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .